Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3038492 Target Snapshot

JAK2/JAK1 · PROTEIN COMPLEX · Homo sapiens

73Compounds
52Assays
8Approved Drugs
102.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P23458. Use UniProt P23458 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P23458 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats JAK2/JAK1 as ChEMBL target CHEMBL3038492, mapped to UniProt P23458. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
JAK2/JAK1
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3038492
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P23458
Tyrosine-protein kinase JAK1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether JAK2/JAK1 is the right protein anchor across sources, using UniProt P23458 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase JAK1
UniProt AccessionP23458
Component TypeProtein
Sequence Length1154 aa

Tyrosine-protein kinase JAK1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as JAK2/JAK1, mapped to UniProt P23458. ChEMBL maps the protein component as Tyrosine-protein kinase JAK1. Sequence length is 1154 aa.

Mapped IDP23458
Review nameJAK2/JAK1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

8
Approved
1
Phase III
2
Phase II
Assay Mix

Activity Type Distribution

IC5091.0
EC5011.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3622821 8.52 IC50 3.0 Approved
CHEMBL5422886 7.85 IC50 14.0 Preclinical
CHEMBL4297507 7.6 IC50 25.0 Clinical
CHEMBL1789941 7.51 IC50 31.0 Approved
CHEMBL5409953 7.43 IC50 37.0 Preclinical
CHEMBL5396554 7.36 IC50 44.0 Preclinical
CHEMBL5404574 7.35 IC50 45.0 Preclinical
CHEMBL5407260 7.32 IC50 48.0 Preclinical
CHEMBL221959 7.29 IC50 51.0 Approved
CHEMBL5412967 7.24 IC50 58.0 Preclinical
Distribution

pChEMBL Value Distribution

12
5.0
16
5.5
13
6.0
20
6.5
17
7.0
4
7.5
0
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

DEUCRAVACITINIB
CHEMBL4435170
Approved 2022
ABROCITINIB
CHEMBL3655081
Approved 2021
FILGOTINIB
CHEMBL3301607
Approved 2020
UPADACITINIB
CHEMBL3622821
Approved 2019
TOFACITINIB
CHEMBL221959
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
Assay Landscape

Assay Landscape

52
Total Assays
55
Tested Compounds
2
Assay Types
Binding — 49 assays, 55 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 36 33 6.5
protein complex format 8 21 6.0
tissue-based format 5 1 5.9
ADME — 3 assays, 4 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 3 6.5
tissue-based format 1 1 5.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine